Patients Stopping Anti-Obesity Injections Regain Pounds Far More Rapidly Compared to Dieters
Fresh analysis suggests that patients who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who halt traditional lifestyle programs.
Published data in a major health publication shows that while overweight people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Users using such medications need to be cognizant of the danger of quick weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original mass in about 18 months.
Comparing Therapies
The study, which looked at dozens of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
Scientists emphasize that individuals who shed pounds through dieting generally see a slower creep back—perhaps 100 grams monthly—once they finish.
Explaining the Fast Rebound
Doctors believe the mechanism of the jabs is key to understanding the accelerated rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating far more likely."
An Ongoing Condition?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the therapy might need to be long-term.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the jabs describe a powerful return of cravings.
"It felt as if a trigger activating and I was suddenly starving," recalled an individual.
This challenge is worsened if individuals have not adopted sustainable dietary or behavioural modifications during treatment.
Significant Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is higher among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while these medications are effective agents for weight loss, they are not a permanent solution and maintained weight loss hinges on integrated behavioural support.